MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity.

By Hang Su, Jian-Rong Yang, Teng Xu, Jun Huang, Li Xu, Yun-fei Yuan, Shi-Mei Zhuang. Cancer Research, 2009

635 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. (2010, neutral): “Expression of this miRNA is downregulated in bladder transitional cell carcinoma, hepatocellular carcinoma, and prostate tumors, which correlates with high Ezh2 levels (Friedman et al., 2009; Su et al., 2009; Varambally et al., 2008).”
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification (2020, background): “miRNA-101 is downregulated by HBx and promotes apoptosis, inhibits autophagy and targets enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), DNA methyltransferase 3A, SRY-box transcription factor 9 (SOX9), and Girdin in HCC (Cao et al., 2016; Su et al., 2009; Wei et al., 2013; Xu et al”
MicroRNAs in development and disease. (2011, background): “In addition, other miRNAs were identified as mediators of apoptosis and are also reduced in HCC, these include miR-101, which targets the antiapoptotic protein Mcl-1 (583), and miR-233, a suppressor of stathmin (667), a microtubule-destabilizing and tumor-promoting protein (129, 204, 429).”
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer (2011, background): “A large and growing body of literature shows the involvement of miRNAs in hepatocarcinogenesis (Meng et al., 2007; Coulouarn et al., 2009; Gramantieri et al., 2009; Ji et al., 2009; Su et al., 2009; Wang et al., 2009; Braconi et al., 2010; Pineau et al., 2010).”